Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 6/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835726 | 0.94 | GLP1R (0.52) | GLP1RRRM1DPP7NOD1TLR2 | |
| SCHEMBL25835340 | 0.92 | GLP1R (0.50) | GLP1RRRM1DPP7NOD1TLR2 | |
| SCHEMBL26032866 | 0.91 | GLP1R (0.55) | GLP1RRRM1DPP7NOD1TLR2 | |
| SCHEMBL26032521 | 0.84 | DPP7 (0.45) | GLP1RRRM1DPP7NOD1TLR2 | |
| SCHEMBL25835481 | 0.81 | DPP7 (0.47) | GLP1RRRM1DPP7NOD1TLR2 | |
| SCHEMBL23895012 | 0.79 | DPP7 (0.73) | RRM1DPP7NOD1GNAI3GNAO1 | |
| SCHEMBL31251746 | 0.79 | DPP7 (0.73) | RRM1DPP7NOD1GNAI3GNAO1 | |
| SCHEMBL24072850 | 0.79 | DPP7 (0.73) | RRM1DPP7NOD1GNAI3GNAO1 | |
| SCHEMBL31619668 | 0.79 | DPP7 (0.73) | RRM1DPP7NOD1GNAI3GNAO1 | |
| SCHEMBL31619646 | 0.79 | DPP7 (0.73) | RRM1DPP7NOD1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | GLP1R 1985/4885RRM1 128/4885DPP7 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.